AC Immune (NASDAQ:ACIU) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

AC Immune (NASDAQ:ACIU) issued its quarterly earnings data on Friday. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.01, FiscalAI reports. The business had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.14 million. AC Immune had a negative return on equity of 84.32% and a negative net margin of 1,642.89%.

AC Immune Price Performance

Shares of NASDAQ:ACIU opened at $3.02 on Friday. The business has a 50-day moving average of $3.15 and a two-hundred day moving average of $3.03. The firm has a market capitalization of $303.24 million, a PE ratio of -3.60 and a beta of 1.64. AC Immune has a 12 month low of $1.43 and a 12 month high of $4.00.

Institutional Investors Weigh In On AC Immune

Several large investors have recently made changes to their positions in ACIU. EFG International AG purchased a new position in shares of AC Immune in the 4th quarter valued at $41,000. Marshall Wace LLP purchased a new stake in AC Immune during the 4th quarter worth $586,000. Dimensional Fund Advisors LP boosted its position in AC Immune by 20.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 213,464 shares of the company’s stock worth $670,000 after purchasing an additional 36,353 shares during the period. Goldman Sachs Group Inc. increased its holdings in AC Immune by 46.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after purchasing an additional 5,920 shares in the last quarter. Finally, Susquehanna International Group LLP acquired a new stake in AC Immune in the 3rd quarter valued at $63,000. Institutional investors and hedge funds own 51.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ACIU. Jefferies Financial Group reissued a “buy” rating and issued a $7.00 target price on shares of AC Immune in a research note on Friday. Wall Street Zen upgraded shares of AC Immune from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of AC Immune in a research report on Wednesday, January 21st. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $9.00.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.